San Diego, California, November 17 (ots/PRNewswire) - - First Phase III Data Presented at the ACR Annual Meeting Roche today announced the results of the first Phase III study in rheumatoid arthritis (RA) conducted by Chugai in Japan which are being presented at the American College of Rheumatology (ACR) ...
Alderley Park, England, November 16 (ots/PRNewswire) - - New Data Add Momentum to AstraZeneca's Novel Oncology Drug, ZD6474 (ZACTIMA[TM]), Which has Already Shown Promising Data in Non-Small Cell Lung Cancer (NSCLC) Preliminary results from a Phase II study showing promising clinical data with ZD6474 ...
London, November 16 (ots/PRNewswire) - - For Non-US Media Only - PROactive Study Also Shows a 37 Percent Reduction in Acute Coronary Syndrome With ACTOS New results from secondary analyses of the landmark PROactive Study found that ACTOS(R) (pioglitazone) significantly reduced the occurrence of fatal ...
Edmonton, Canada, November 16 (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA), a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics, announced today that effective immediately, Joseph Koziak, who served as Executive Vice President is no longer an officer of the company. About Isotechnika Isotechnika Inc. is an international biopharmaceutical ...
Paris, November 16 (ots/PRNewswire) - - Emea Approves New Treatment for Chronic Stable Angina Procoralan (ivabradine, Servier), the first selective and specific If inhibitor, has received marketing authorization in 27 European countries from the European Medicines Evaluation Agency (EMEA) for the ...
Macclesfield, England, November 15 (ots/PRNewswire) - - For Health Professional Press Only - For International Journalists Only - Not for US Media - Retrospective ISEL Study Analysis Identifies Potential Indicator of Response to Treatment With gefitinib in Advanced NSCLC patients Data presented ...
Dallas, Texas, November 14 (ots/PRNewswire) - - FIELD Confirms Fenofibrate Produces Macrovascular and Microvascular Benefits in Diabetic Patients Without Previous Cardiovascular Disease Although Primary Endpoint is not met Results of the largest intervention study ever conducted for the prevention of ...
Dallas, Texas, November 14 (ots/PRNewswire) - - CAFÉ Study Shows Central Aortic Pulse Pressure Important Determinant of Cardiovascular Outcomes A new sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)(1), presented during a late breaking clinical trial session of the American Heart ...
Edmonton, Canada, November 7 (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247. A summary of the results is as follows: - All primary and secondary efficacy endpoints were achieved at 24 weeks - Efficacy endpoints were ...
International Bureau for Epilepsy (IBE) & UCB
Sydney, November 7 (ots/PRNewswire) - - With Photos The first live performance of Brain Storm, a theatre production focused on epilepsy was staged today at the 2005 World Congress of Neurology in Sydney, Australia. Brain Storm dramatizes the devastating effect that uncontrolled seizures can have on the ...
Edmonton, Canada, November 4 (ots/PRNewswire) - - ATTN: Business/Assignment Editors: EDMONTON, Canada, November 4 /PRNewswire/ -- Isotechnika Inc. will announce the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247 on Monday, November 7th at 7:00 a.m. EST/5:00a.m. MST. Management will ...
Paris, November 2 (ots/PRNewswire) - The European School of Oncology (ESO) presented this year's joint winners of the ACE (Awarding Cancer Enlightenment) Reporter Award 2005 -- Viktoria Kun, Health Correspondent on the Hungarian national daily newspaper Nepszabadsag, and Ioanna Soufleri, Science Editor on the Greek national daily newspaper To Vima -- with euro 5,000 each at an award ceremony held today at the European ...
Bunnik, The Netherlands (ots/PRNewswire) - - Three Lead Compounds are Progressing Into Next Clinical Phase AM-Pharma B.V., a privately owned biopharmaceutical company, engaged in the pre-clinical and early clinical development of novel compounds to treat infectious and inflammatory diseases and their consequences, announces that a major B-financing round has been successfully completed. The company attracted ...
Basel, Switzerland (ots/PRNewswire) - The news that the innovative new cancer drug Tarceva(R) (erlotinib) is now becoming available across the EU will provide a glimmer of hope to over 380,000 people in Europe this year who have received the devastating news that they have lung cancer. Not only has Tarceva demonstrated a striking survival benefit (42.5 per ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has entered into an agreement with Eisai Co., Ltd. to license their novel adjuvant, E6020, for use in the development of new vaccines to treat or prevent human illnesses. E6020 is a chemically synthesized adjuvant that will be ...
Madrid (ots/PRNewswire) - Zeltia S.A. (ZEL SM; ZEL.MC), Spanish pioneer and leader in biotechnology, announces 9 months results to September 2005. Research and Development spend amounted to EUR31 million during this period, a 10% increase year on year. 83% of this amount was accounted for by PharmaMar. Notable advances at PharmaMar in the last quarter include ...
Basel, Switzerland (ots/PRNewswire) - Following today's European approval of Boehringer Ingelheim's boosted protease inhibitor tipranavir (APTIVUS(R)), European patients now have the chance to benefit from the potent combination of the fusion inhibitor FUZEON (enfuvirtide) and boosted tipranavir in addition to ...
Amsterdam, The Netherlands (ots/PRNewswire) - - Valdoxan(R) (agomelatine) Provides Antidepressant Efficacy With the Additional Clinical Benefit of Sleep Improvement With no Effect on Daytime Vigilance The first melatonergic antidepressant, Valdoxan(R) (agomelatine), offers an innovative new approach to the treatment of depression. Valdoxan combines ...
Amsterdam, The Netherlands (ots/PRNewswire) - - New data also demonstrate SEROQUEL tolerability benefits versus other atypicals in schizophrenia and reinforce therapeutic potential in bipolar disorder Seroquel (quetiapine), olanzapine and risperidone are equally effective in patients experiencing first episode psychosis, according to data presented today ...
Alderley Park, England (ots/PRNewswire) - - For Health Professional Press and Non-UK Journalists Only Newly released top-line results from the BOLDER II (BipOLar DEpRession) study have underlined the potential for SEROQUEL (quetiapine fumarate) in the treatment of patients with major depressive episodes associated with bipolar disorder. In BOLDER ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - Lilly ICOS LLC (Lilly ICOS) (NYSE: LLY and Nasdaq: ICOS) is releasing its financial results for the third quarter ended September 30, 2005, proudly reporting net income of US$19.8 million, compared to a net loss of US$21.4 million in the 2004 third quarter. Worldwide sales of Cialis(R) (tadalafil)(1) in the third quarter of 2005 totaled US$195.1 million, ...
Berlin, Germany (ots/PRNewswire) - - For Healthcare Professional Journalists - Not for distribution to US media - Randomised, Placebo-Controlled Study Shows Discontinuation of Pramipexole Leads to Rapid Worsening of Symptoms - Two new, randomised, placebo-controlled studies presented this week at the ...
Basel, Switzerland (ots/PRNewswire) - - New potent combinations make suppression of virus to undetectable levels more achievable for treatment-experienced HIV patients The importance of the drug FUZEON(R) (enfuvirtide) in the management of HIV has been officially recognised by the US Department of Health ...
World Federation for Mental Health
Washington D.c. (ots/PRNewswire) - - Dr Benedetto Saraceno of WHO Will Keynote a Symposium to Mark 2005 WMHD in Washington D.C. The 13th World Mental Health Day (WMHD) will be celebrated today in many countries and this year examines the close relationship between mental and physical health across all ...
Cheshire, England (ots/PRNewswire) - ATTN: Health Press Most people with bipolar disorder believe that successful treatment would significantly improve their quality of life and that treatment satisfaction is achieved by efficacy and tolerability, according to final results from the large scale Thinking ...
London (ots/PRNewswire) - - Takeda's ACTOS(R) (pioglitazone HCl) on Top of Standard Treatment Demonstrates Significant Cardiovascular Benefits A study published in The Lancet today shows that Takeda's ACTOS(R) (pioglitazone HCl), an oral glucose lowering medication, significantly reduces the combined risk ...
Dar Es Salaam, Tanzania (ots/PRNewswire) - - The Abbott Fund and the Government of Tanzania Dedicate New Hospital Facilities to Meet Long-Term Needs of Patients with HIV/AIDS and Other Diseases In a ceremony today, Abbott CEO Miles White joined Tanzanian President Benjamin William Mkapa in dedicating a ...
Indianapolis and Ingelheim, Germany (ots/PRNewswire) - Your mother, your friend, your sister - chances are one of these three women have suffered from the symptoms of stress urinary incontinence (SUI), but she has been too embarrassed to admit it. This is just one of the staggering facts revealed by a ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika Inc. ("Isotechnika") and Atrium Medical Corporation ("Atrium") jointly announced today the signing of an exclusive worldwide licensing agreement for the use of TAFA93 and ISA247 specifically with drug eluting ...
Lyon, France et Swiftwater, Pennsylvanie (ots/PRNewswire) - - First Combination Vaccine Candidate in the U.S. Designed to Protect Infants and Young Children against Diphtheria, Tetanus, Pertussis, Polio, and Hib Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN), (NYSE: SNY), announced today the acceptance of a Biologics ...